BioNTech beginnt Pha
BioNTech beginnt Phase-1-Studie mit prophylaktischem Impfstoffkandidaten BNT163 gegen Herpes-Simplex-Virus-2
December 21, 2022 06:45 ET | BioNTech SE
Erste klinische Studie untersucht Sicherheit und Immunogenität des prophylaktischen Herpes-Virus-Impfstoffkandidaten BNT163 erstmalig am MenschenBNT163 ist der erste Kandidat aus BioNTechs...
BioNTech Starts Phas
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
December 21, 2022 06:45 ET | BioNTech SE
First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine...
AYRO Announces Results of Annual Meeting of Stockholders and Provides Summary of Business Update
December 15, 2021 09:25 ET | AYRO, Inc.
AUSTIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro...
DSG Global Inc. and Imperium Motor Company Experience Successful Twelve Days at LA Auto Show with Strong Sales and Media Recognition
December 01, 2021 09:00 ET | DSG Global Inc.
SURREY, British Columbia, Dec. 01, 2021 (GLOBE NEWSWIRE) -- DSG Global, Inc. (OTCQB: DSGT) ("DSGT" or the "Company") and Imperium Motor Company are pleased to announce the completion of a much...
Excision logo 2.png
CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure
November 18, 2019 12:00 ET | Excision BioTherapeutics
Oakland, CA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- At the 2019 International Symposium on Neurovirology, Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases,...